Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.
Link esterno per Kedrion Biopharma
Kedrion Biopharma ha diffuso questo post
Per garantire in Italia un accesso equo e uniforme alle terapie, bisogna rendere più attrattivo l’approvvigionamento di plasmaderivati. Le aziende farmaceutiche fanno già la loro parte investendo risorse crescenti per rendere disponibile un numero sempre maggiore di questi farmaci. Migliorando innovazione tecnologica ed efficienza produttiva. #HackDonor2024
Last year we were honoured to meet Jaina and Alina in one of our new collection centers in Prague - two sisters, in a desperate attempt to escape the war in Ukraine, seek refuge in the Czech Republic. Filled with a deep sense of gratitude towards the people who have welcomed them, they decide to give back by donating plasma at a local center. This story isn't just about donating plasma; it's about the community that comes together around a plasma center. It's about people who put humanity first and want to make a difference in the lives of those who will receive plasma-derived therapies. Their kindness shows that even in hardship, compassion prevails, reminding us of the power of collective action in making a difference. Watch the video to hear their words and join us in celebrating all the donors around the world, everyday. #WBDD2024 #Plasma #PlasmaDonation #Donors
🎉 Oggi celebra con noi la 𝐆𝐢𝐨𝐫𝐧𝐚𝐭𝐚 𝐌𝐨𝐧𝐝𝐢𝐚𝐥𝐞 𝐝𝐞𝐥 𝐃𝐨𝐧𝐚𝐭𝐨𝐫𝐞 𝐝𝐢 𝐒𝐚𝐧𝐠𝐮𝐞 𝐞 𝐝𝐢 𝐏𝐥𝐚𝐬𝐦𝐚! Un giorno fondamentale per onorare tutti coloro che, in Italia e nel mondo, con questo gesto di puro altruismo, assicurano la disponibilità di trattamenti per milioni di pazienti. Grazie per essere stati con noi in questo viaggio 🧳 e vi lasciamo con l’ultimo #PlasmaQuiz! #HackDonor2024 #WBDD2024 #Plasma #PlasmaDonation Farmindustria
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn
💫🚲 Siamo alla quarta tappa del nostro viaggio del plasma! A un giorno dalla Giornata Mondiale del Donatore di Sangue e di Plasma, vi presentiamo anche oggi il nostro #PlasmaQuiz. 🎮 Dopo aver scoperto l’immenso valore della donazione, del plasma e il percorso che questa preziosa risorsa fa per diventare una terapia, approfondiamo le popolazioni di pazienti che aiuta. #HackDonor2024 #WBDD2024 #Plasma #PlasmaDonation Farmindustria
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn
The President of IPOPI - International Patient Organisation for Primary Immunodeficiencies, Martine Pergent, during a symposium recently held in Turkey for a large audience of Turkish pediatric and adult immunologists, highlighted 𝐭𝐡𝐞 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐛𝐞𝐬𝐭 𝐦𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐈𝐦𝐦𝐮𝐧𝐨𝐝𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐢𝐧 𝐭𝐡𝐞 𝐭𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧 𝐟𝐫𝐨𝐦 𝐜𝐡𝐢𝐥𝐝𝐡𝐨𝐨𝐝 𝐭𝐨 𝐚𝐝𝐮𝐥𝐭𝐡𝐨𝐨𝐝 for a better quality of life of patients. This meeting, organized with the unconditional grant of Kedrion Biopharma, also involved 𝐏𝐫𝐨𝐟. 𝐃𝐫. 𝐎̈𝐦𝐮̈𝐫 𝐀𝐫𝐝𝐞𝐧𝐢𝐳, who chaired the symposium and explained 𝐭𝐡𝐞 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐬𝐭𝐚𝐭𝐮𝐬 𝐨𝐟 𝐏𝐫𝐢𝐦𝐚𝐫𝐲 𝐈𝐦𝐦𝐮𝐧𝐨𝐝𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐢𝐞𝐬 𝐢𝐧 𝐓𝐮𝐫𝐤𝐞𝐲, which has a high incident rate and despite this there is still a lack of attention and importance given to this issue.
⏰ È iniziato il conto alla rovescia! Mancano solo 4 giorni alla Giornata Mondiale Del Donatore di Sangue e Plasma istituita nel 2005 dall’OMS per celebrare e ringraziare tutti coloro che, in Italia e nel resto del mondo, grazie a questo gesto di autentico altruismo, garantiscono la disponibilità di terapie a milioni di pazienti. 🩸 In questa settimana così ricca di significato, metti alla prova le tue conoscenze sul mondo della donazione di plasma e sul ruolo svolto dai plasmaderivati nella cura di numerose patologie. Sei pronto a giocare con noi? Ogni giorno, a partire da oggi fino al 14 giugno, rilanceremo la campagna dedicata di Farmindustria e vi proporremo un nuovo quesito. La sfida inizia oggi con il nostro primo #PlasmaQuiz.
Questo contenuto non è disponibile qui
Accedi a questo contenuto e molto altro nell’app LinkedIn
🌱 𝐎𝐮𝐫 𝟐𝟎𝟐𝟑 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐬 𝐨𝐮𝐭 🌍 We are thrilled to announce the release of our latest 𝐒𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝟐𝟎𝟐𝟑! This report highlights the strides we've made towards sustainability across all facets of our operations. Sustainability is not just a goal-it's at the core of our Values. It involves the ability to anticipate tomorrow's events with the confidence achieved through impactful actions initiated today. This past year, our sustainability efforts have grown hand in hand with the economic and financial advancements of the new Kedrion. Key highlights from this Report include: 🤝 Community engagement and partnerships 🌿 Environmental initiatives and progress 📈 Impact metrics and future goals Moving forward, we remain committed to investing in initiative that enhance our operations, ensuring 𝐭𝐡𝐞 𝐡𝐢𝐠𝐡𝐞𝐬𝐭 𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 𝐬𝐨𝐜𝐢𝐚𝐥 𝐚𝐧𝐝 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞, 𝐭𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲, 𝐚𝐧𝐝 𝐚𝐜𝐜𝐨𝐮𝐧𝐭𝐚𝐛𝐢𝐥𝐢𝐭𝐲. #Sustainability #2023SustainabilityReport #GreenFuture #CorporateResponsibility ➡️ https://lnkd.in/dP-BZVxg
The official adoption of the #SoHORegulation by the Council of the European Union represents a crucial step towards the growth of plasma collection. Kedrion will work side by side PPTA to ensure donor health and guarantee a resilient supply of life-saving plasma-derived medicines to patients across Europe.
Today, the Council of the European Union officially adopted the #SoHORegulation. We would like to thank our member companies for their continuous support and commitment. PPTA's advocacy efforts align with the call for greater EU strategic autonomy. A flexible legislative framework allows Member States to establish and maintain plasma collection models and infrastructure that reflect the particularities and needs of their individual healthcare systems. Plasma donation via apheresis is a safe procedure and an efficient way to collect plasma. Alongside our members, we supported evidence-based policies that prioritise donor safety and health. Each day, thousands donate plasma under expert care and in accordance with stringent rules. Plasma donation procedures are rigorously and continuously monitored. The growth in EU plasma volumes collected over the past 20 years has come mainly from the private sector. This shows the value of the coexistence of public and private plasma collection models. Such models have been successfully implemented in Austria, the Czech Republic, Germany and Hungary, with plasma collection rates well above the EU average. PPTA will continue to emphasise the necessity of increasing plasma collection and support policies that recognise the unique nature of PDMPs. We remain committed to working with all stakeholders to ensure a reliable supply of plasma for fractionation and continue our mission of saving lives. Read our statement here: https://lnkd.in/exMeJNea Grifols, Takeda, Kedrion Biopharma, European Commission, Belgian Presidency of the Council of the European Union 2024, European Parliament, #PlasmaProteins #PatientCare #DonorHealth #EUNeedsMorePlasma #SoHORegulation
🌍 𝐖𝐫𝐚𝐩 𝐮𝐩 𝐨𝐟 𝐭𝐡𝐞 𝟐𝟎𝟐𝟒 𝐖𝐨𝐫𝐥𝐝 𝐅𝐞𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐇𝐞𝐦𝐨𝐩𝐡𝐢𝐥𝐢𝐚 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 🌟 🎥 Watch the video to catch the most impactful moments from this year's conference. From groundbreaking research to inspiring patient stories, this congress showcased the latest advancements in bleeding disorders care and management. Let's continue to collaborate and drive progress in the hemophilia and other coagulations disorder community! #WFHCongress2024 #TreatmentForAll #GlobalHealth #BleedingDisorder World Federation of Hemophilia / Fédération mondiale de l'hémophilie
🌍 𝐄𝐧𝐬𝐮𝐫𝐢𝐧𝐠 𝐄𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐁𝐥𝐞𝐞𝐝𝐢𝐧𝐠 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐌𝐫. 𝐆𝐚𝐫𝐫𝐢𝐝𝐨, 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐖𝐅𝐇 During the 𝟐𝟎𝟐𝟒 𝐖𝐨𝐫𝐥𝐝 𝐅𝐞𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐇𝐞𝐦𝐨𝐩𝐡𝐢𝐥𝐢𝐚 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬, we had the privilege of speaking to Mr. Garrido (President of World Federation of Hemophilia / Fédération mondiale de l'hémophilie), about a critical topic affecting patients globally: 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. In our interview, he shared compelling perspectives on why this issue matters and what steps can be taken to bridge gaps in care. Bleeding disorders are a condition that require lifelong management, and access to therapies can significantly impact patients' lives. As advocates for health equity, it's crucial to address disparities in access, ensuring that everyone, regardless of location or resources, can receive the treatments they need. More than 3000 attendees gathered at this year’ World Federation of Hemophilia Congress, recently held in Madrid, as it is recognized as one of the most important appointments for the bleeding disorders communities. ⤵️ 𝐖𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐡𝐞𝐫𝐞 to gain valuable insights. #WFHCongress2024 #TreatmentForAll #GlobalHealth #BleedingDisorder